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IT is beyond dispute that when repeated subcutaneous injections of the iron-
dextrancomplex
" Imferon
" aregiven torats, mice, hamsters orrabbits,malignant
tumours may arise in high incidence at the injection site (Richmond, 1957, 1959,
1960 ; Haddow and Horning, 1960 ; Lundin, 1961 ; Haddow, Roe and Mitchley,
1964). It has been argued that the animal experiments in which tumours have
been induced involved the injection of doses of iron-dextran much larger in
relation to body weight than any used clinically ; and that in all the tumour-
bearing animals there was also evidence of gross iron overloading (Goldberg and
Smith, 1958, 1960a, 1960b ; Baker, Goldberg, Martin and Smith, 1961). Haddow
and Horning (1960) and later Roe (1961) pointed out that since the size of body cells is similar in man and laboratory animals, the actual dose, and not the body weight, may be the critical factor in determining the induction of tumours at the
site of injection of a foreign material into the body: a particular volume of
material will come into contact with approximately the same number of body cells in the rat as it does in man. On the question of iron-overloading, which
according to Baker et al. (1961) delays the removal of iron from the injection site, Haddow and Roe (1964), whilst unable to dismiss its importance entirely, pointed
out that injection-site tumours may appear in response to doses of iron-dextran
much lower than those used in other experiments so far described in the literature.
The purpose of the experiment to be described below was two-fold. The
first was to see whether the incidence and time of appearance of tumours in rats
given a fixed number ofinjections ofiron-dextran would be affectedbydistributing the injections between two, four or six sites, instead ofgiving them, as in previous experiments (Haddow and Horning, 1960), all into the same site. It was hoped that the results of the experiment would indicate whether, in the case of courses
ofinjections ofImferongiven clinically, it was betteralways to inject the material
into the same site or to use multiple sites. The second object was to see whether
iron-dextran increased the incidence of tumours in tissues distant from the site of
injection. In previous experiments a higher than expected incidence of such
tumours had been encountered (Haddow, 1963 ; Langvad, 1964).
MATERIALS AND METHODS
Rat8
128 Male rats of the Chester Beatty stock Wistar strain were used for the
experiment. At six weeks of age they were divided randomly into 4 groups of
24 and I of 32, and thereafter housed in metal cages 8 to a cage. Throughout the802 F. J. C. ROE, A. HADDOW, C. E. DUKES AND B. C. V. MITCHLEY
experiment they were fed a cubed diet, Diet 86, prepared by Messrs. Dixon &
Sons of Ware, Herts. This diet contains whole ground wheat-50%, whole
ground barley-25%, white fish meal-7%, meat and bone meal-6%; dried
brewer's yeast-5%, clried grass meal-5%, cod liver oil-I%, and salt-I%.
Water was given ad libitum. Rats of the Chester Beatty strain are especially
large and at the age of 6-7 weeks, when the first injection was given, the animals
weighed approximately 200 g. each.
Iron-dextran complex: Imferon
" lmferon
" (Bengers' Laboratories) was used for all injections. This
preparation of iron-dextran contains 50 mg. iron per ml.
Experimental details
The four groups which contained 24 rats each were treated, from the 7th
week of life onwards, with 24 once-weekly subcutaneous injections of 0-5 ml.
Imferon. In the case ofGroup I all theinjections were into the same site, namely,
the right groin. Rats ofGroup 2 were injected alternately in the right groin and
left posterior axillary region, each site being injected once every second week for
a total of 12 times. Rats of Group 3 were injected into both groins and both
posterior axillary regions in the following rotation: right groin, left posterior
axilla, left groin, right posterior axilla. In this case each site was injected every
fourth week and only 6 times in all. ln the case ofGroup 6, six sites were used,
the two additional ones being in the sacral region near the root of the tail and a
point between the anterior angles of the scapulae. Again the sites were injected
in rotation, each site receiving 4 injections at 6-week intervals. Fig. I shows the
positions ofthe injection sites and indicates the order in whichthey wereinjected.
The group which contained 32 rats (Group 5) was left untreated but in all
other respects kept under the same conditions as Groups 1-4.
Animals were examined twice each week and killed ifthey developed rapidly
growing or large tumours at any of the injection sites, or if they became sick
from any other cause. Occasionally, animals which had not previously been
noted as sick were found dead. Except where autolytic changes precluded it, a
careful and full post-mortem examination was carried out. Tissue was taken for
histological examination from eachinjection site, irrespective ofwhether a tumour
was thought to be present or not. At the same time sections were prepared from
suspected tumours of other sites in the body.
RESULTS
Tumours Ari-sing at the Sites ofInjection of Iron-Dextran
The analysis of the experimental results proved somewhat more difficult than
anticipated. As in all long-term experiments of this kind some of the animals
died from intercurrent infections before they developed tumours. In addition,
two rats ofGroup I and one ofGroup 2, which were thought to have tumours at
the site of injection of iron-dextran, died and autolysis prevented histological
assessment. Another problem was that increasing thickening, due to general
fibrosis, often preceded the appearance of tumours and the exact time of change
from this state to neoplasia was difficult to determine by simple inspection and803 IRON-DEXTRAN CARCINOGENESIS IN RATS
palpation of the living animal. The tumours which arose at the injection sites
were of several different histological varieties. In some cases large tumours
proved to be benign fibromata, whereas much smaller ones were early sarcomata,
as judged by the usual histological criteria. In the case of animals killed because
of a large tumour at one of multiple injection sites, tumours in earlier stages of
development were found at some or all of the remaining sites. Sometimes the
presence of these additional tumours was suspected whilst the animal was still
alive, and sometimes they were discovered for the first time at post-mortem.
Frequently, mttltiple neoplastic foci were found at a single injection site. Finally,
since only one or two sections prepared from each injection site were examined
microscopically, it is possible that early tumours were in some cases missed.
The results, as far as tumours at the sites ofinjection are concerned, are given
in Table 1. The highest incidence ofrapidly growing 8arcomata at the injection 8ite
TABLEI.-Tumours at the Sites ofInspection of Iron-Dextran
Nurnber of rats 24
Nurnber exarnined post-rnortern 9.)
Number ofinjection sites per rat I
Nurnber of rats killed because of a histologically rnalig- 14
nant turnour at one or rnore injection sites
Average time at which rats were killed for such 501
turnours (days)
Time of appearance of first rnalignant tumour in 329
group (days)
Total nurnber of rats which developed rnalignant 14
turnours at one or rnore injection site
Total number of rats which developed benign or 14
malignant tumours at one or more injection site
Number of rats dying without a tumour at any injec- 8
tion site
Average survival of all rats in Group (days) 505
Averao,e survival of rats examined post-mortem (days) 514
Proportion of injection sites examined post-mortem 141/2,'
showing tumour formation (63
-60.
2
24
23
2
6
3
24
24
4
9
4
24
23
6
3
5
32
28
0
667 706 674
460 449 522
6 9 7
7 12 10
16 12 13 28
539 582 608
541 582 622
!2 11/46 29/96 17/138
%) (23 9%) (30
- 2%) (12
- 3%)
573*
596*
* N.B.-Five apparently healthy control rats were killed on the 732nd day of the experiment after all the rats in the 4 other groups had died or been killed because they were sick. If these
animals had been permitted to live out their life-span, the average survival of the controls would
have been close to that ofGroup 4.
was encountered in Group 1. In this group the first undoubted sarcoma appeared after 329 days and the animal had to be killed because of it on the 354th day. Altogether, 14 out of 22 rats of this group (64%) which came to post-mortem
developed large sarcomata for which they had to be killed, the average time of
killing being 501 days. As stated above, autolysis prevented post-mortem
examination in the case of two rats ; both ofthese were considered on the basis of
macroscopic examination to have sarcomata, but have been excluded from the
results shown in Table L No sarcomata ofmicroscopic dimensions and no benign
tumours were found at theinjection site in any oftheremaining rats ofthis group. The lowest incidence ofrapidly growing sarcomata for which rats had to be killed
was encountered inGroup 4 : only 3 out of 23 rats (I3%) developed such tumours
and these were killed after an average of 574 days. However, when injection sites showing sarcomatkt of microscopic dimensions were taken into account the804 F. J. C. ROE, A. HADDOW, C. E. DUKES AND B. C. V. MITCHLEY
incidence was 7 out of 23 (30%); and when, in addition, rats bearing benign
tumours at the injection site were also included, the total incidence of animals
with injection-site tumours became 10 out of 23 (43%). It was not uncommon
for multiple sites to be involved simultaneously by tumour formation. Another
way, therefore, of assessing the results in Groups 1 and 4 is to compare the ratio
of the numbers of tumours to the number of sites injected with iron-dextran (see
final column of Table I). It may be seen that in Group 1, 14 out of the 22 sites
examined post-mortem developed tumours, i.e. 64% of the sites injected. In
Group 4, 17 out ofthe 138 sites examined (i.e. 12.3%) had tumours. The 22 sites
in Group 1 each received 6 times as many injections as the 138 sites in Group 4.
Thus, the incidence of tumours at the injection site in the two groups was
approximately proportional to the number of injections and to the total dose of
iron-dextran introduced into the site.
In general, the results in Groups 2 and 3 were intermediate between those in
Groups 1 and 4 with regard to (1) the incidence of large sarcomata for which rats
had to be killed, (2) the time of appearance of the first sarcoma, (3) the average
time of killing because of large sarcomata, (4) the incidence of microscopic
sarcomata and of benign tumours at the injection site, and (5) the ratio oftumour-
ous sites to sites injected. However, in some respects the tumorigenic response in
Group 2 was less impressive than that in Group 3, which was surprising. In
Group 3 for instance, tumours developed in 29 out of 96 sites examined (30-2%),
whereas in Group 2, the corresponding figures were 11 out of 46 sites (23.9 Y).
It is undoubtedly difficult to obtain a clear picture of the results of the
experiment. One of the main reasons for this arises from the difficulty of in-
terpreting the lesions which were regarded by us as early sarcomata. It cannot,
in our view, be seriously doubted that these were truly malignant in nature, but
it is difficult to judge how quickly they would have become large and obvious
tumours if the animals bearing them had been allowed to live longer.
Perhaps the most helpful way of looking at the results is to compare average
survival (see Table I) and the incidence of animals which developed no injection-
site tumours in the various groups. Only 8 rats of Group 1, which were examined
post-mortem, had no tumour at the injection site. The comparable figures for
Groups 2, 3 and 4, in which multiple injection sites were available for tumour
development, were 16, 12 and 13, respectively. Using this method of assessment
of the results it would seem to be advisable, where multiple injections of iron-
dextran are to be given, to use multiple rather than just a single site. Similarly,
a comparison of the average survival in the 5 groups indicates a progressive
increase with increasing numbers of sites used: the averages for Groups 1-4 were
505, 539, 582 and 608 days, respectively. As explained in the footnote to Table I,
5 quite healthy control rats were killed off on the 732nd day (i.e. shortly after
the last of the iron-dextran treated rats had had to be killed because of tumour
development or because it was sick). Had these five rats been allowed to live
out their life span the average survival of the control group would have been
close to that of Group 4.
Pathology of tumours arising at sites of injection of iron-dextran
The earliest change discernible at the injection site on gross examination was a
palpable thickening. This was associated with the microscopic appearance of
fibrosis in relation to collections of macrophages containing iron pigment. From805 IRON-DEXTRAN CARCINOGENESIS IN RATS
such fibrotic areas large tumours arose, sometimes suddenly, sometimes insidi-
ously. The more rapidly growing of these large tumours proved on histological
examination to be fibrosarcomata or pleomorphic sarcomata. Some of the more
slowly growing tumours were sarcomata and some benign fibromata. There was
a marked difference between Group I and the other groups in that no benign
tumours were seen in the former. Moreover, the most pleomorphic and mitotic-
ally active tumours were seen in this group.
Sarcomata ofmicroscopic size (Fig. 2 and 3) were seen at one or more injection
sites in Group 2 (2 cases), Group 3 (6 cases) and Group 4 (5 cases). Multiple
neoplastic lesions of the same type, or of different types, were often seen in a
single injection site (Fig. 4 and 5).
Apartfrom sarcomata andfibromata, two small adenomatous lesions were seen.
Presumably these arose from mammary gland elements, though all the rats used
in the experiment were males.
TABLEII.-Tumoui-sArisingRemotelyfrom theInjection-site8 in Iron-Dextran Ti-eated Rats
Number of rats with
Number of rats benign or malignant Details of benign tumours Details ofnialignant tumours
examined tumours other thaii r-- ---) (_
Group post-mortem at injection sites No. Description No. Description
1 22 4 3 Papilloma of bladder I Lymphorna.
(Fig. 6 and 7)
Manimarv fibroade-
noma
Ganglioneurorna
(Fig. 8)
2 23 2 1 Mammary fibroma I Myxosarcoma oflip. 3 24 3 1 Polypoid adenoma of 2 Sarcoma of lung.
colton (Fig. 9 and Lymphorna.
10)
4 23 3 0 3 Abdominal sarcoma.
Osteosarcoma
(Fig. II).
Lymphoma.
92 12 (13 00X/
1 5 7 (7-6%)
5 (Controls) 28 3 (10 7%) I Multiple adenomata 2 Lymphoma.
(exocrine) of pan- (7 I%) Abdominal sarcoma.
creas (Fig. 12 and
13).
Tumours Arising Remotelyfrom the Sites ofInjection ofIron-Dextran
Details of tumours arising remotely from the injection sites are given in Table
1I. An interesting variety of tumours, some benign and some malignant, were
seen. The overall incidence of both benign and malignant tumours in the iron-
dextran treated- rats (Groups 1-4) was closely similar to that in the untreated
controls (Group 5). The data are insufficient for comment regarding possible differences in the types of tumour arising in treated and control animals. (Some of the tumours are illustrated in Fig. 6-13).
DISCUSSION
The fact that benign or malignant tumours arose at 71 out of 302 injection sites in 92 rats treated with iron-dextran indicates once again that the carcino-806 F. J. C. ROE, A. HADDOW, C. E. DUKES AND B. C. V. MITCHLEY
genicity ofthis material given in this way is of no low order. On the other hand,
the results of the experiment throw no light on the importance of the presence of
iron-overloading in the genesis of tumours at the site ofinjection of iron-dextran
(Golberg and Smith, 1958, 1960a, 1960b ; Baker, Golberg, Martin and Smith,
1961). Each rat in Groups 1-4 received a total of 12 ml. ofiron-dextran (600 mg.
iron). On the basis of comparative body weight, this treatment would be the
equivalent of the introduction of over 2 litres of iron-dextran into a non-anaemic
70 kg. man. It is not certain from the present experiment that any injection-site
tumours would have arisen if the rats had not been overloaded with iron. On the
other hand, it is quite clear that the introductionofquite small total doses of iron-
dextran into a single iniection site (in an iron-overloaded rat) is capable ofgiving
rise to tumours. Each injection site in the case of rats ofGroup 4 of the present
experiment received only 4 injections of 0-5 ml. iron-dextran, a total of 2 ml., and
the risk of a benign or malignant tumour arising at such a site was as high as
12-3% (the risk of a malignant tumour developing was 8-7%). The fact that
multiple malignant tumours were sometimes seen in sitesexposed to only 2 ml of
EXPLANATION OF PLATES
FiG. I.-Positions of the six injection sites.
Fie.. 2.-Subcutaneous injection site from left groin of rat of Group 4. This site received
four injections of 0
- 5 ml. iron-dextran at six-weekly intervals, the last injection being
given approximately 50 weeks before the animal was killed because of the development of
large sarcomata at each of 2 other injection sites. Large deposits ofsiderophages lie in the
dermis and subcutaneous tissues and a rounded early sarcomatous lesion can be seen in the
deepest part of the section. H. & E. x 5.
FIG. 3.-Edge of early sarcoma from the left posterior axillary region of a rat of Group 4
killed 2 years after the start of treatment. The lesion extends into fatty tissue and consists
of fibroblasts and fibrocytes. Some of the cells near the edge of the lesion show a myxo-
matous change. This was a frequent finding in such lesions. H. & E. x 120.
FIG. 4.-Encapsulated fibroma partly surrounded by actively growing fibro-sarcoma from
left axilla of a rat of Group 3 killed 2 years after the start of the experiment. As in other
cases, the tumours have arisen in close proximity to deposits of iron-laden macrophages.
H.&E. x3.
FIG. 5.-Multiple early sarcomata at the site of injection of Imferon in right axilla of the
same rat asdepicted inFig. 2. At least 5 distinct foci are visible in this section. H. & E. x 3.
FIG. 6.-Multiple benign papillomata involving half the circumference of the bladder of a rat
of Group 1. This animal was killed during the 47th week of the experiment because of a
large sarcoma at the site of injection. The bladder lesion was an incidental finding.
H.& E. x 4-5.
FiG. 7.-Same as Fig. 6, to show well-differentiated nature of transitional epithelium of which
the tumour consists. H. & E. x 255.
Fie.. 8.-Ganglioneuroma ofthe adrenal medulla from a rat ofGroup 1, which was killed with a
large injection-site sarcoma during the 94th week of the experiment. H. & E. x 560.
FIG. 9.-Polypoid adenoma of colon from rat of Group 3 killed because of tumours at 3 of
four injection sites 2 years after the start of treatment. The tumour is causing considerable
distension of the gut. H. & E. x 7.
FIG. IO.-Same as Fig. 9 showing the well-differentiated acinar structure of the tumour.
H. & E. x 255.
FIG. II.-Multiple deposits ofosteogenic sarcoma in the lung of an untreated rat of Group 5.
The animal was killed because it became sick during the 90th week of the experiment.
Similar deposits were present in several other organs. The site of the primary lesion was
not ascertained. H. & E. x 3
-5.
FIG. 12.-Adenomatosis ofthe pancreas of an untreated rat ofGroup 5 killed at the termination
of the experiment during the 105th week. The pancreas is seen attached to a loop of small
gut. Three large and multiple smaller adenomatous nodules may be seen. H. & E. x 3
- 5.
FiG. 13.-Same as Fig. 12 showing the well-differentiated acinar structure of one ofthe nodules
and a prominent mitotic figure in one of the cells. H. & E. x 515.BRITISH JO-LTRNAL OF CANCER. Vol. XVIII, No. 4.
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iroii-dextraii (see Fig. 5) suggests that smaller doses still may have been effective.
Clearlv, the next step is to see whether iron-overloading is esseiltial or not for
the inductioii of tumours by these relatively small doses of iron-dextran. Experi-
ments to determiiie this have been beguii.
Oi-i tl-ie whole, the results of the experiment suggest that where repeated
injections of iron-dextraii are to be given clinically it would be safer to distribute
the injected material througli many sites rather than introduce it all into the
same site. This conclusioii, which can be i-io more than teiitative, is based on the
following facts: (1) Rapidly growing tumours appeared in higher incidence in
animals wliich received all the injections into the same site (Group 1). (2) The
most malignailt tumours, as judged by histological appearances, were almost all
in Group 1. (3) I'he average survival time increased with the numbers of injec-
tioii sites, though it must be pointed out that no attempt was made to remove
or otherwise treat large tumours. Successful treatment may have eliminated
differences in survival time between the groups. (4) Although the total incidence
of ii-ijection site tumours was higher in rats of Groups 3 and 4, several of them
were benign and few 1-iad reached the stage at which they threatened the life of
the aiiimal before it became sick or died from other causes. In this connection it
mav be argued that if the sequence of events seen in these rats were reflected in
man but earlier in relation to his life-span, the use ofmultiple sites rather than a
single site would increase, rather than decrease, the hazards ofiron-dextran treat-
meiit. For, in these circumstances, the early sarcomata seen in old rats close to
the eiid of their life-span would be matched by sarcomata which had adequate
time to become lethal tumours within the life-span of man. Clearly, such
speculatioi-i goes beyond the limits set by the availability of factual evidence.
Tiie second questioii posed in the introduction was :
" Does iron-dextraii
treatment lead to an increased incidence of tumours in tissues remote from the
sites of injectioii ?" The results give no indication that the incidence of such
tumours is increased. The occurrence of a papillary papilloma of the bladder
and of ai-i adenocareinoma of the colon in the iron-dextran treated rats deserves
commeiit. Two examples of ganglioneuroma of the adrenal medulla were re-
ported bv Haddo,", and Horning (1950), both in carcinogen treated rats. We
liave, in fact. iiever encountered tumours of an of these types in untreated
rats of the Chester Beatty Wistar strain, and no such tumours were seen in the
contemporary untreated control animals (Group 5). The remaining tumours were
of tvpes seeii from time to time in the strain and are therefore un-noteworthy. The overall incidence ofboth benign and malignant tumours, apart frominjection- site tumours, was closely similar in the treated and control groups. Langvad (1964) recently reported a rather different result. Fifty male and 50 female
mice of the St/Eh A strain were injected repeatedly with Imferon until total
doses of up to 2 ml. per mouse (I00 mg. Fe) had been given. Overall tumour
incidei-ices of 7% in males and 58% in females were encountered. Corresponding tumour rates in untreated controls were 0% and 20%, respectively. The author
points out that experiments with oncogenic viruses were in progress at the same
time as the Imferon experiment and that cross contamination cannot be ruled
out. However, the result would not be less interesting if the increased tumour
incidence were shown to be the combined effect of Imferon and an oncogenic virus. Clearly, despite the results of the experiment reported here, the possibilitv that iron-dextran predisposes to cancer at distant sites cannot be ruled out.
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SUMMARY
Twenty-four subcutaneous injections of 0-5 ml. Imferon, given at weekly
intervals to male Wistar rats, gave rise to sarcomata irrespective of whether the
injected material wasgivenalways into the same site, or whether it was distributed
between 2, 4 or 6 sites. Animals injected in one site only developed rapidly
growing and generally more malignant tumours than rats injected at multiple
sites. On the other hand, the total number ofinjection-site tumours was higher
in the groups with 4 or 6 different injection-sites. In Group 4, of 138 injection
sites, each of which received only 4 injections of Imferon at 6-weekly intervals,
17 developed tumours. It is pointed out that all the rats in this experiment
were
" over-loaded
" with iron and the results therefore throw no light on the
importance ofiron-overloading indetermining thegenesis ofinjection site tumours.
A variety of tumours of sites other than those at which Imferon was injected
were seen in all the four test groups and in the control group. There was no
indication that iron-dextran treatment increased the incidence of tumours other
than at the sites at which it was injected.
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